Literature DB >> 27872498

The cryptic IRF2BP2-RARA fusion transforms hematopoietic stem/progenitor cells and induces retinoid-sensitive acute promyelocytic leukemia.

J V Jovanovic1, M C Chillón2, C Vincent-Fabert3, R Dillon1, E Voisset1, N C Gutiérrez2, R G Sanz2, A A M Lopez2, Y G Morgan4, J Lok4, E Solomon1, E Duprez3, M G Díaz2, D Grimwade1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27872498     DOI: 10.1038/leu.2016.338

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  10 in total

1.  IRF2BP2-RARA t(1;17)(q42.3;q21.2) APL blasts differentiate in response to all-trans retinoic acid.

Authors:  Samir Mazharuddin; Anuja Chattopadhyay; Moshe Y Levy; Robert L Redner
Journal:  Leuk Lymphoma       Date:  2018-01-19

2.  Savior Siblings Might Rescue Fetal Lethality But Not Adult Lymphoma in Irf2bp2-Null Mice.

Authors:  Ragnar O Vilmundarson; Niloufar Heydarikhorneh; An Duong; Tiffany Ho; Kianoosh Keyhanian; Fariborz Soheili; Hsiao-Huei Chen; Alexandre F R Stewart
Journal:  Front Immunol       Date:  2022-07-04       Impact factor: 8.786

3.  Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts.

Authors:  Jana M Ellegast; Gabriela Alexe; Amanda Hamze; Shan Lin; Hannah J Uckelmann; Philipp J Rauch; Maxim Pimkin; Linda S Ross; Neekesh V Dharia; Amanda L Robichaud; Amy Saur Conway; Delan Khalid; Jennifer A Perry; Mark Wunderlich; Lina Benajiba; Yana Pikman; Behnam Nabet; Nathanael S Gray; Stuart H Orkin; Kimberly Stegmaier
Journal:  Cancer Discov       Date:  2022-07-06       Impact factor: 38.272

Review 4.  Current views on the genetic landscape and management of variant acute promyelocytic leukemia.

Authors:  Xiang Zhang; Jiewen Sun; Wenjuan Yu; Jie Jin
Journal:  Biomark Res       Date:  2021-05-06

5.  A rare case of acute promyelocytic leukemia with IRF2BP2-RARA fusion; and literature review.

Authors:  Yiping Liu; Fang Xu; Hong Hu; Jingjing Wen; Jing Su; Qiaolin Zhou; Wen Qu
Journal:  Onco Targets Ther       Date:  2019-08-02       Impact factor: 4.147

Review 6.  PLZF-RARα, NPM1-RARα, and Other Acute Promyelocytic Leukemia Variants: The PETHEMA Registry Experience and Systematic Literature Review.

Authors:  Marta Sobas; Maria Carme Talarn-Forcadell; David Martínez-Cuadrón; Lourdes Escoda; María J García-Pérez; Jose Mariz; María J Mela-Osorio; Isolda Fernández; Juan M Alonso-Domínguez; Javier Cornago-Navascués; Gabriela Rodríguez-Macias; María E Amutio; Carlos Rodríguez-Medina; Jordi Esteve; Agnieszka Sokół; Thais Murciano-Carrillo; María J Calasanz; Manuel Barrios; Eva Barragán; Miguel A Sanz; Pau Montesinos
Journal:  Cancers (Basel)       Date:  2020-05-21       Impact factor: 6.639

7.  Interferon regulatory factor 2 binding protein 2b regulates neutrophil versus macrophage fate during zebrafish definitive myelopoiesis.

Authors:  Luxiang Wang; Shuo Gao; Haihong Wang; Chang Xue; Xiaohui Liu; Hao Yuan; Zixuan Wang; Saijuan Chen; Zhu Chen; Hugues de Thé; Yiyue Zhang; Wenqing Zhang; Jun Zhu; Jun Zhou
Journal:  Haematologica       Date:  2020-01-31       Impact factor: 9.941

Review 8.  Atypical Rearrangements in APL-Like Acute Myeloid Leukemias: Molecular Characterization and Prognosis.

Authors:  Luca Guarnera; Tiziana Ottone; Emiliano Fabiani; Mariadomenica Divona; Arianna Savi; Serena Travaglini; Giulia Falconi; Paola Panetta; Maria Cristina Rapanotti; Maria Teresa Voso
Journal:  Front Oncol       Date:  2022-04-12       Impact factor: 5.738

Review 9.  Classic and Variants APLs, as Viewed from a Therapy Response.

Authors:  Marie-Claude Geoffroy; Hugues de Thé
Journal:  Cancers (Basel)       Date:  2020-04-14       Impact factor: 6.639

Review 10.  Acute Promyelocytic Leukemia: A Constellation of Molecular Events around a Single PML-RARA Fusion Gene.

Authors:  Alessandro Liquori; Mariam Ibañez; Claudia Sargas; Miguel Ángel Sanz; Eva Barragán; José Cervera
Journal:  Cancers (Basel)       Date:  2020-03-08       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.